Skip to main navigation Skip to search Skip to main content

Discovery and Structure–Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors

  • Nicolas Boutard
  • , Arkadiusz Białas
  • , Aleksandra Sabiniarz
  • , Paweł Guzik
  • , Katarzyna Banaszak
  • , Artur Biela
  • , Marcin Bień
  • , Anna Buda
  • , Barbara Bugaj
  • , Ewelina Cieluch
  • , Anna Cierpich
  • , Łukasz Dudek
  • , Hans Michael Eggenweiler
  • , Joanna Fogt
  • , Monika Gaik
  • , Andrzej Gondela
  • , Krzysztof Jakubiec
  • , Mirek Jurzak
  • , Agata Kitlińska
  • , Piotr Kowalczyk
  • Maciej Kujawa, Katarzyna Kwiecińska, Marcin Leś, Ralph Lindemann, Monika Maciuszek, Maciej Mikulski, Paulina Niedziejko, Alicja Obara, Henryk Pawlik, Tomasz Rzymski, Magdalena Sieprawska-Lupa, Marta Sowińska, Joanna Szeremeta-Spisak, Agata Stachowicz, Mateusz M. Tomczyk, Katarzyna Wiklik, Łukasz Włoszczak, Sylwia Ziemiańska, Adrian Zarębski, Krzysztof Brzózka, Mateusz Nowak, Charles Henry Fabritius
  • Selvita S.A.
  • Almac Group
  • S.A
  • Merck KGaA
  • Jagiellonian University in Kraków
  • Captor Therapeutics Inc.
  • LifeArc
  • Current address: Grupa Adamed

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

Energy and biomass production in cancer cells are largely supported by aerobic glycolysis in what is called the Warburg effect. The process is regulated by key enzymes, among which phosphofructokinase PFK-2 plays a significant role by producing fructose-2,6-biphosphate; the most potent activator of the glycolysis rate-limiting step performed by phosphofructokinase PFK-1. Herein, the synthesis, biological evaluation and structure–activity relationship of novel inhibitors of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), which is the ubiquitous and hypoxia-induced isoform of PFK-2, are reported. X-ray crystallography and docking were instrumental in the design and optimisation of a series of N-aryl 6-aminoquinoxalines. The most potent representative, N-(4-methanesulfonylpyridin-3-yl)-8-(3-methyl-1-benzothiophen-5-yl)quinoxalin-6-amine, displayed an IC 50 of 14 nm for the target and an IC 50 of 0.49 μm for fructose-2,6-biphosphate production in human colon carcinoma HCT116 cells. This work provides a new entry in the field of PFKFB3 inhibitors with potential for development in oncology.

Original languageEnglish
Pages (from-to)169-181
Number of pages13
JournalChemMedChem
Volume14
Issue number1
DOIs
Publication statusPublished - 8 Jan 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cancer
  • enzymes
  • glycolysis
  • inhibitors
  • metabolism

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • General Pharmacology, Toxicology and Pharmaceutics
  • Organic Chemistry

Fingerprint

Dive into the research topics of 'Discovery and Structure–Activity Relationships of N-Aryl 6-Aminoquinoxalines as Potent PFKFB3 Kinase Inhibitors'. Together they form a unique fingerprint.

Cite this